Oncology
OncoX inks licensing deal worth over $26m for NSCLC therapy
US-based ABVC BioPharma has sold the rights to its botanical drug extract therapy, BLEX 404, for the treatment of non-small…
Theolytics secures funds to advance oncolytic adenovirus therapy
UK-based biotechnology company Theolytics has concluded a funding round securing a total of £19m ($24.5m) to advance the development of…
Ultimovacs downsizes to funnel funds to cancer vaccine programme
Ultimovacs has implemented cash-saving strategies, including a 40% workforce reduction, to extend its reserves into Q4 2025. The operational adjustments…
Portage mulls company closure, pauses enrolment for lead clinical programme
US-based Portage Biotech is cash-strapped and has started looking for strategic alternatives including a wind-down of the company. The company…
Sanofi advances NK cell engager to Phase II for blood cancer treatment
Sanofi has moved its natural killer (NK) cell engager candidate SAR443579/IPH6101 to a Phase II trial evaluating the drug’s use…
Candel wins FDA orphan drug designation for pancreatic cancer drug
The US Food and Drug Administration (FDA) has granted Candel Therapeutics’ immunotherapy candidate CAN-2409 (aglatimagene besadenovec) orphan drug designation for…
Century secures $60m in stock sale and buys preclinical cell therapy biotech
Century Therapeutics has acquired US-based Clade Therapeutics, which specialises in allogeneic cell therapies, to expand its pipeline of cancer and…
Novartis signs deal for Arvinas’ prostate cancer therapy
Novartis has signed an exclusive strategic licence agreement for Arvinas’ ARV-766, a new treatment for prostate cancer. ARV-766 is an investigational,…
OSE wins French govt grant for Phase III trial for cancer vaccine
OSE Immunotherapeutics has received €8.4m ($9m) in non-dilutive funding from the ‘France 2030’ plan funded by the French Government. The…
Lisata wins FDA orphan drug status for bone cancer candidate
The US Food and Drug Administration (FDA) has granted orphan drug designation for Lisata Therapeutics’s LSTA1 (certepetide) for the treatment…
